Author details

Full Name

Udayan Guha

Affiliation

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36470425	Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.	J Biol Chem	2023
37190191	Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.	Cancers (Basel)	2023
37243155	A Novel Recognition by the E3 Ubiquitin Ligase of HSV-1 ICP0 Enhances the Degradation of PML Isoform I to Prevent ND10 Reformation in Late Infection.		2023
35139387	Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.	Cell Rep	2022
35440132	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.	Nat Commun	2022
34638461	Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.	Cancers	2021
34283064	Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.	Cancers (Basel)	2021
33850265	SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.	Oncogene	2021
33727228	Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.	Cancer Res	2021
33504652	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.	Sci Transl Med	2021
34391887	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.	Mol Cell Proteomics	2021
34388376	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.	Cancer Cell	2021
34818552	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies.	Cell Rep	2021
32793495	Longitudinal Monitoring of and Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.	Frontiers in Oncology	2020
32483558	Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.	Cell Rep Med	2020
32464188	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study.	Chest	2020
32744066	A meta-analysis and analysis of polymorphic variants conferring breast cancer risk in the Indian subcontinent.	Future Oncology	2020
30840888	APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.	Cell Rep	2019
31639039	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.	J Immunother Cancer	2019
30617155	Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.	Mol Cell Proteomics	2019
29252124	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.	J Clin Oncol	2018
30139066	Meta-Analysis of Polymorphic Variants Conferring Genetic Risk to Cervical Cancer in Indian Women Supports CYP1A1\nas an Important Associated Locus		2018
29900338	Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity.	Data Brief	2018
29660496	Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.	J Proteomics	2018
27780780	Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.	J Thorac Oncol	2017
28819023	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.	Cancer Res	2017
28331001	Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.	Mol Cell Proteomics	2017
29076184	Association of 12 polymorphic variants conferring genetic risk to lung cancer in Indian population: An extensive meta-analysis.	Environmental and Molecular Mutagenesis	2017
28214415	Consolidative local therapy in oligometastatic patients.	Lancet Oncol	2017
27494838	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.	Oncotarget	2016
26802155	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.	Ann Oncol	2016
27135835	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.	Hum Vaccin Immunother	2016
27900369	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.	Cold Spring Harb Mol Case Stud	2016
25605897	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.	Proc Natl Acad Sci U S A	2015
25596284	ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.	Cancer Res	2015
25592632	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.	Lancet Oncol	2015
25667274	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	J Clin Oncol	2015
25404012	Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.	Proteomics	2015
25735773	Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.	Cancer Discov	2015
23857959	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.	Ann Oncol	2013
28510178	SH3 domains: modules of protein-protein interactions.	Biophysical Reviews	2013
23052255	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clin Cancer Res	2012
21641113	Keratinocyte expression of calcitonin gene-related peptide Î²: implications for neuropathic and inflammatory pain mechanisms.	Pain	2011
18776048	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.	Proc Natl Acad Sci U S A	2008
18537141	Bone morphogenetic protein regulation of enteric neuronal phenotypic diversity: relationship to timing of cell cycle exit.	Journal of Comparative Neurology	2008
15115823	Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.	Journal of Neuroscience	2004
15331398	Bone morphogenetic protein signaling regulates postnatal hair follicle differentiation and cycling.	Am J Pathol	2004
14973275	Target-derived BMP signaling limits sensory neuron number and the extent of peripheral innervation in vivo.	Development (Cambridge)	2004
12217322	In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb.	Developmental Biology	2002
10845723	Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors.	Gene Therapy	2000